| Project/Area Number |
18K15086
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 49020:Human pathology-related
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
MATSUMURA Mai 横浜市立大学, 医学部, 助教 (50812997)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | EGFR変異肺腺癌 / MUC21 / 微小乳頭状亜型 / 全エクソーム解析 / バイオインフォマティクス解析 / 肺癌 / 肺腺癌 / EGFR変異 |
|---|
| Outline of Final Research Achievements |
Our recent study demonstrated that malignant grade of EGFR-mutated lung adenocarcinoma (LADC) was determined by micropapillary (mPAP) element. I revealed that MUC21 was related to mPAP element of EGFR-mutated LADCs, and the tumors expressed MUC21 protein had poor prognosis. To uncover the potential molecular basis of mPAP element, I investigated somatic mutations specific to mPAP element in EGFR-mutated LADC. mPAP and other elements were separately collected from frozen tissue sections of EGFR-mutated LADC by the laser capture microdissection system and were subjected to whole exomes sequencing analyses. Through bioinformatics analysis, somatic mutations which was cofirmed by sanger-sequencing specific to mPAP elements were identified. Finally, I made “Highly malignant EGFR-mutated LADCs gene panel”. These gene mutations might be related to the highly malignant activity of mPAP element.
|
| Academic Significance and Societal Importance of the Research Achievements |
これまで肺がん臨床の現場で分子治療標的となる遺伝子変異は、腫瘍発生に関わるドライバー変異であった。我々が作成した「高悪性度EGFR肺腺癌パネル」に含まれる後発変異が治療標的となれば、EGFRチロシンキナーゼ阻害薬（EGFR-TKI）との併用により、腫瘍の悪性化や薬剤耐性化の阻止に役立つ可能性がある。
|
